Inhibition of Cyclophilins Affects Lipid Trafficking and HCV Secretion
Author Information
Author(s): Leah J. Anderson, Lin Kai, Teresa Compton, Brigitte Wiedmann
Primary Institution: Novartis Institutes for Biomedical Research, Inc
Hypothesis
NIM811 may inhibit viral replication by impairing the cellular machinery on which HCV relies to traffic cofactors necessary for formation of an active replication complex.
Conclusion
NIM811 treatment leads to impaired lipid and protein trafficking, resulting in decreased secretion of both apoB and HCV particles.
Supporting Evidence
- NIM811 treatment resulted in enlarged lipid droplets and decreased apoB secretion.
- Changes in lipid droplet morphology were dependent on the expression of viral proteins.
- NIM811 inhibited the release of HCV RNA and infectious particles from infected cells.
Takeaway
When a specific drug called NIM811 is used, it makes fat droplets in liver cells bigger and stops a virus from being released, which helps us understand how to fight the virus better.
Methodology
The study used HCV replicon cells and JFH1 HCVcc infected cells to assess the effects of NIM811 on lipid droplet morphology and apoB secretion.
Limitations
The study primarily focuses on specific cyclophilins and may not account for other factors influencing HCV replication and secretion.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website